Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary bilia

Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)

Approval based on the positive GLISTEN phase III trial with regulatory reviews underway in the EU, UK, Canada and China